It was encouraging to see the market respond positively to Patrys’ (ASX:PAB) announcement of its preclinical study highlighting the potential for using deoxymab antibodies as targeting agents in antibody drug conjugates (ADCs).
Patrys CEO and MD, Dr James Campbell, was interviewed by Kara Ordway on AusBiz to discuss this study, and other recent milestones.
Take a look.